Tumor mutational burden (TMB) by next-generation sequencing is emerging as a biomarker of response to immunotherapy agents in cancer patients. However, heterogeneity in experimental and analytical protocols, as well as bioinformatic pipelines, influence the variability for TMB estimation and reporting, demonstrating the need for standardization and harmonization of TMB assessment methodology across assays and clinical centers. Friends of Cancer Research (Friends) and the Quality Assurance Initiative Pathology (QuIP), have collaborated to coordinate efforts for international multi-stakeholder initiatives to address this need.
Tumor Mutational Burden (TMB): Harmonization and Future Application
Jeff Allen, PhD, Friends of Cancer Research, Washington, DC, USA
Objectives:
- Review TMB as a biomarker for immunotherapy response in cancer patients.
- Describe methodologies for TMB assessment and quantification.
- Review the many factors that influence TMB assessment.
Duration: 0.75 hr
Recording Date: November 9, 2019
CME/CMLE credit: 0.75 hr
Last day to purchase course and CE claim credit: December 24, 2022
